Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011706 · ClinicalTrials.gov registry record · Phase 2
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Aclaris Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT07011706 is a Phase 2 study of Atopic Dermatitis and Eczema that is actively recruiting participants, run by Aclaris Therapeutics. The registered enrollment target is 96 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT07011706, a Phase 2 study of Atopic Dermatitis and Eczema, is actively recruiting participants, sponsored by Aclaris Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ATI-045
Study Locations (20)
California
- Aclaris Clinical Site - Beverly Hills
- Aclaris Study Site - Encinitas
- Aclaris Clinical Site - Encino
- Aclaris Clinical Site - Huntington Beach
- Aclaris Study Site - Los Angeles
- Aclaris Study Site - Oceanside
- Aclaris Study Site - Santa Monica
- Aclaris Clinical Site - Sherman Oaks
- Aclaris Clinical Site - Thousand Oaks
Florida
- Aclaris Study Site - Coral Gables
- Aclaris Clinical Site - Hollywood
- Aclaris Clinical Site - Jacksonville
- Aclaris Clinical Site - Margate
- Aclaris Study Site - North Miami Beach
- Aclaris Study Site - Sweetwater
- Aclaris Study Site - Tampa
- Aclaris Clinical Site - Wellington
Arizona
- Aclaris Clinical Site - Phoenix
- Aclaris Clinical Site - Tucson
Arkansas
- Aclaris Study Site - Bryant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011706
The ClinicalTrials.gov registry entry for NCT07011706 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (84% lower). The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07011706 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07011706 about?
NCT07011706 is a clinical study titled "ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis". This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
What is the current status of trial NCT07011706?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2025-05-30. Estimated completion is 2026-10.
What conditions does trial NCT07011706 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Dermatitis, Atopic, AD.
What interventions are being tested in trial NCT07011706?
The interventions under investigation include: Placebo (DRUG), ATI-045 (DRUG).
Who is sponsoring clinical trial NCT07011706?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011706 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.